Parkinson hastalığının klinik seyri ve tedavi seçenekleri

Abstract

SUMMARY This study has been done in patients with Parkinson's Disease who applied to GATA Neurology Clinic. 78 patients ( 46 male, 32 female ) whose ages range between 42 and 83 years were included to this study. The patients were followed for 4-24 months ( mean 11.5 months ) and controlled 3-10 times ( mean 5 times ) during the study. 24 patients took Selegiline, 17 monotherapy of Dopamin agonists, 19 Selegiline and Levodopa, 18 combination of Dopamin agonists and Levodopa during the study. We gave Selegiline with the dosage of 10 mg/day to the patients taking only this drug and 1 1 of these patients needed the second Antiparkinsonien drug after a mean period of 7.4 months. Selegiline with the dosage of 10 mg/day and Levodopa with the mean dosage of 328.9 mg/day were given to the patients in group of Selegiline and Levodopa combination. After the dose of Levodopa was regulated an another third drug was added to the therapy in 4 patients ( 21.8 % ) due to aggrevation of symptoms. Pribedil with the mean dosage of 123.5 mg/day was given to the patients in the Dopamin agonists group. A second drug was added to the therapy in 9 patients ( 52.9% ) because of aggrevation of symptoms after 5.7 months. Levodopa ( 343.75 mg/day ) and Dopamine agonists ( Pribedil 135 mg/day, Lisurid 0.45 mg/day, Bromocriptin 36.25 mg/day ) were given to the patients in combination Dopamin agonists and Levodopa. A third drug was added to the patients in this group ( 16.6 % ) after 12.3 months because of aggrevation of symptoms. 48During the study, only 4 patients showed drug side effects. Low frequency of side effects in likely due to follow-up period of short duration. As a result, monothrapy done with Selegiline or Dopamin agonists delay the need of Levodopa in patients with newly diagnosed Parkinson's Disease. A combination Levodopa and Dopamin agonists is the most effective therapy for the patients who have been diagnosed formerly and taken Antiparkinsonien medication. 49

SUMMARY This study has been done in patients with Parkinson's Disease who applied to GATA Neurology Clinic. 78 patients ( 46 male, 32 female ) whose ages range between 42 and 83 years were included to this study. The patients were followed for 4-24 months ( mean 11.5 months ) and controlled 3-10 times ( mean 5 times ) during the study. 24 patients took Selegiline, 17 monotherapy of Dopamin agonists, 19 Selegiline and Levodopa, 18 combination of Dopamin agonists and Levodopa during the study. We gave Selegiline with the dosage of 10 mg/day to the patients taking only this drug and 1 1 of these patients needed the second Antiparkinsonien drug after a mean period of 7.4 months. Selegiline with the dosage of 10 mg/day and Levodopa with the mean dosage of 328.9 mg/day were given to the patients in group of Selegiline and Levodopa combination. After the dose of Levodopa was regulated an another third drug was added to the therapy in 4 patients ( 21.8 % ) due to aggrevation of symptoms. Pribedil with the mean dosage of 123.5 mg/day was given to the patients in the Dopamin agonists group. A second drug was added to the therapy in 9 patients ( 52.9% ) because of aggrevation of symptoms after 5.7 months. Levodopa ( 343.75 mg/day ) and Dopamine agonists ( Pribedil 135 mg/day, Lisurid 0.45 mg/day, Bromocriptin 36.25 mg/day ) were given to the patients in combination Dopamin agonists and Levodopa. A third drug was added to the patients in this group ( 16.6 % ) after 12.3 months because of aggrevation of symptoms. 48During the study, only 4 patients showed drug side effects. Low frequency of side effects in likely due to follow-up period of short duration. As a result, monothrapy done with Selegiline or Dopamin agonists delay the need of Levodopa in patients with newly diagnosed Parkinson's Disease. A combination Levodopa and Dopamin agonists is the most effective therapy for the patients who have been diagnosed formerly and taken Antiparkinsonien medication. 49